Baker Avenue Asset Management
NVCR icon

Baker Avenue Asset Management’s NovoCure NVCR Stock Holding History

Baker Avenue Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Sell
10,231
-627
-6% -$9.49K ﹤0.01% 802
2026
Q1 		$118K Buy
+10,858
New +$136K ﹤0.01% 742
2023
Q1 		– Sell
-8
Closed -$587 – 1711
2022
Q4 		$587 Buy
+8
New +$602 ﹤0.01% 1262

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Baker Avenue Asset Management's NVCR Position: Q2 2026 in Review

Baker Avenue Asset Management reduced its NovoCure (NVCR) stake by 5.8% in Q2 2026, selling an estimated $9.49K and leaving 10,231 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #802.

Baker Avenue Asset Management first reported a position in NVCR in Q4 2022 and has held it in 3 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Baker Avenue Asset Management held 10,231 shares of NovoCure worth $155K as of Q2 2026.
  • Baker Avenue Asset Management sold 627 NovoCure shares in Q2 2026, an estimated $9.49K.
  • NovoCure made up ﹤0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #802 holding.
  • Baker Avenue Asset Management first reported a position in NovoCure in Q4 2022 and has held it in 3 quarters since.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.